Description
Retatrutide – Premium Research Peptide (RUO)
Overview
Retatrutide (LY-3437943) is a next-generation triple-agonist synthetic peptide, engineered to simultaneously stimulate the GLP-1, GIP, and glucagon receptors, delivering unmatched metabolic modulation for advanced scientific investigations. This innovative mechanism positions Retatrutide as one of the most potent tools in metabolic and endocrinological laboratory research.
Why Choose Retatrutide from ProPeptides.net?
-
Laboratory-Grade Purity & Quality
Synthesized under stringent parameters and validated by advanced analytical methods to ensure high purity, stability, and bioactivity. -
Mechanism of Action
-
GLP-1 receptor activation: Enhances insulin secretion, suppresses appetite, and promotes satiety.
-
GIP receptor activation: Improves metabolic efficiency and augments fat metabolism.
-
Glucagon receptor activation: Drives fat oxidation and elevates energy expenditure, fostering metabolic flexibility.
-
-
Proven Research Benefits
Clinical and preclinical data highlight remarkable outcomes including up to 24.2 % mean body weight reduction at 48 weeks, along with significant improvements in glycemic control and metabolic health markers. -
Applications in Scientific Research
Ideal for exploring metabolic regulation, hormonal signaling, obesity and diabetes mechanisms, energy homeostasis, and multi-pathway receptor crosstalk. -
Stability & Handling
Designed with lipid acylation for enhanced half-life and reduced enzymatic degradation—perfect for extended in vitro or in vivo (non-clinical) studies.
Handling & Storage Guidance
-
Form: Lyophilized peptide—long-term stability when stored at recommended conditions.
-
Storage Conditions: Store lyophilized form at 2–8 °C. After reconstitution, keep refrigerated and use within 28 days.
Usage & Disclaimer
Strictly intended for laboratory research use only. Not for human or veterinary use or any clinical application. Intended only for qualified researchers and institutions.





Reviews
There are no reviews yet.